Amneal Pharmaceuticals has received approval from the Food and Drug Administration for a dementia treatment and a drug targeting certain types of brain tumors, as well as tentative approval for a drug ...

whole-cell Glioblastoma Phase II (23), concurrent controls Improved PFS and OS [143] NDV Ulster, whole-cell Advanced head and neck Phase II (18), historical controls Improved OS [154] NDV Ulster ...

Catastrophic macropinocytosis, also called methuosis, as a nonapoptotic cell death associated with cytoplasmic vacuolization, has gained increasing attention, largely because of its potential ...

According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM ... It is under development for the treatment of spindle cell squamous cell carcinoma, giant cell carcinoma, ...

The Allen Brain Cell Atlas (ABC Atlas) aims to empower researchers worldwide to explore and analyze multiple whole-brain datasets simultaneously. As the Allen Institute and its collaborators continue ...

This important study presents genome-wide high-resolution chromatin-based 3D genomic interaction maps for over 50 diverse human cell types and integrates these data with pediatric obesity GWAS. The ...

Vancouver, BC, January 15, 2025--(T-Net)--AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell ...

The researchers describe how they used sEVs, which are engineered in the lab from human cells, to target a cell-surface receptor called DR5 (death receptor 5) that many tumor cells have.

According to precedent and due to his status, Yoon will probably be assigned a solitary cell, likely bigger and better appointed than the standard 6.56 square metre (71 square feet) single cells.

Founded in 2016, the Fremont, Calif-based Neuralink is currently working on offering digital autonomy to those with quadriplegia. By embedding threads containing electrodes within the human brain ...